Company intelligence / Profile preview
Bexson Biomedical
Santa Barbara, California, United Statesbexsonbiomedical.com ↗
- Ownership
- Private
- Employees
- ~25
- Development stage
- Other
01
Overview
Lead subcutaneous ketamine formulation (BB106) is in preclinical development. Technology platform SEVALENT enables subcutaneous dose delivery for a range of small molecules and has demonstrated improved pH and osmolality compatibility in preclinical tests. No results from human clinical trials have been reported as of October 2025.
- Therapeutic areas
- NeurologyPsychiatry
- Modalities
- Small moleculeDevice
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
03
Partnerships
Stevanato Group
Beyond the preview
Go deeper on Bexson Biomedical.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Bexson Biomedical.